has been a loss of about Rs. 120 crores by increase in the re-quoted price; about Rs. 50 crores because of variation in the exchange rate; and about Rs. 400 crores in terms of loss of revenue; and

(c) if so, what steps have been taken by Government to avoid these losses

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRI KALPNATH RAI) : (a) to (c) All the parties (including M/s. Alsthom, France) who had purchased the bid documents when the tenders were first floated, were intimated to re-bid for the Kawas project. No decision has been taken so far in respect of award of the contract.

**Prices** of Combitlame

3. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to state:

(a) what is the price of combiflame at which it is being marketed at present and since when this is being marked at this price;

(b) whether it is a fact that his Ministry fixed the price of this product under DPCO, 1979;

(c) if so, when and what price was fixed;

(d) whether it is also a fact that the price was re-fixed under DPCO, 1987;

(e) if so, when and what price was fixed;

(f) whether it is a fact that the company neither implemented the price fixed under DPCO, 1979 nor under DPCO, 1987 and overcharged the poor people;

(g) whether it is a fact that his Ministry received complaints in this regard; and

(h) if so, what are the details thereof and action taken by Government thereon?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) as per Indian Pharmaceutical Guide, 1988, price charged for 10's Strip of Combiflam Tablets by M/s. Roussel Pharmaceuticals (India) Ltd., was Rs. 12.19.

(b) and (c) A price of Rs. 7.68 was fixed under DPCO, 1979 for this formulation pack on 5-11-1986.

(d) and (e) A revised price of Rs. 4.90 was *sou-moto* fixed by the Govt, for this pack as Category-I formulation under DPCO, 1987 on 2-12-1988.

(f) to (h) In reply to a show cause notice issued by the Govt., the Manufacturer company M/s. Carews Pharmaceutical Ltd. has claimed that being an SSI unit, they are exempted from price control on their Category-Il formulations. With the shifting of Paracetamol from Schedule I of DPCO, 1987 to Schedule II, w.e.f. 18-1-1989, Combiflam now falls under Category-II. The matter is being further examined.

**Prices of Troxyvon and Butaproxyvon**

**4. SHRI M. KADHARSHA** : Will the Minister of **INDUSTRY** be pleased to state:

(a) whether it is a fact that the prices of Proxyvon and Butaproxyvon are still being overcharged by the drug company;

(b) when and what were the prices of these products fixed for the first time under DPCO 1979 and what were the prices fixed under **DPCO 1987;**